Governing Biotechnology
By George Annas,
Global Agenda Magazine
| 02. 13. 2006
Developments in biotechnology have made possible species-changing and even species-endangering procedures, says George Annas. We urgently need a global governance structure to regulate them.
Albert Einstein cogently observed that "imagination is more important than knowledge." He could have gone further. Moral imagination is more important than scientific imagination. The unmet challenge for science at the beginning of the 21st century is to develop a global bioethics governance system that can help to ensure that biomedical technology enhances human life, and does not degrade or end it.
Paradoxically, the global biotechnology research agenda is facing backwards and forwards at the same time. Looking back, we are trying to react to threats of global pandemics, bioterrorism, and biowarfare. Looking forwards, we are striving to use new biomedical technologies not only to cure or prevent disease but also to physically modify humans in ways that could change our concept of humanity.
So far the world is taking governance of backward-looking technologies more seriously than the forward-looking ones. This is probably because the world has had lots of experience of pandemics and war, because...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...